Abstract
Methods:We retrospectively studied 26 and 24 patients treated with cetuximab (Cmab) and panitubumab (Pmab), respectively, for unresectable advanced colorectal cancer at our department.
Results:The respective findings for treatment with Cmab and Pmab were as follows:first-, second-, and third- or later line therapy was applied in 1, 5, and 20 cases and 3, 2, and 19 cases; Cmab monotherapy and Cmab combined with irinotecan therapy were performed in 14 and 12 cases, and Pmab monotherapy and Pmab combined with FOLFIRI therapy were performed in 16 and 8 cases; the response rate was 33.3 and 16.7%; the disease control rate was 61.1 and 66.7%; time to treatment failure was 4.0 months and 6.1 months; infusion reaction was observed in 2 and 0 cases; and skin toxicity (acne-like rash) was observed in 50.0% and 58.3% including only one case with Grade 3.
Conclusion:With both Cmab and Pmab, although most cases were treated with third- or later line monotherapy, anti-EGFR antibody therapy for unresectable advanced colorectal cancer was effective and tolerated, with favorable efficacy and an acceptable overall toxicity profile.
